Efficacy and safety of lirafugratinib in patients with FGFRi-naïve cholangiocarcinoma harboring FGFR2 fusions/rearrangements

Antoine Hollebecque, et al.

Phase II study of durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair genes alterations

Teresa Macarulla, et al.

Impact of Postoperative ctDNA Dynamics on Eligibility for ALTAIR Randomized Trial in Patients with Colorectal Cancer: Implications for Clinical Trial Enrollment

Hideaki Bando, et al.

FOxTROT: predictive effects of ERBB2 (HER2) and ERBB3 (HER3) on neoadjuvant panitumumab benefit in RAS/BRAF wild-type locally advanced colon cancer (LACC)

Jordan Wesley Appleyard, et al.

SOX (S-1 Plus Oxaliplatin) Combined With Anti-PD-1 Antibody With or Without CAR-like T-Cell Immunotherapy in Previously Untreated Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma: Interim Results of an Open-Label, Randomized, Controlled Phase II Trial

Qin Liu, et al.

NRG-GI004/SWOG-S1610: COlorectal cancer dMMR Immuno-Therapy (COMMIT) study －A randomized phase III study of atezolizumab monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with dMMR or MSI-H metastatic colorectal cancer－

Caio Max Sao Pedro Rocha Lima, et al.

Perioperative PD-1 Antibody Toripalimab Combined with Chemotherapy versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of the Prospective, Randomized, Phase 2 NEOSUMMIT-01 Trial

Shu-Qiang Yuan, et al.

Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01

Elena Elimova, et al.